Karl Elmqvist
Directeur/Membre du Conseil chez AnaCardio AB
Profil
Karl Elmqvist is currently an Investment Manager at Flerie Invest AB since 2022.
He is also a Board Observer at AnaCardio AB since 2022.
Previously, he worked as an Analyst at Imperial Consulting, Inc. in 2016, a Foundation Doctor at Guy's & St Thomas' Charity from 2020 to 2021, an Intern at Tetra Pak Holdings AB in 2015, an Intern at Qvartz AB in 2018, and a Project Manager at Doctrin AB from 2019 to 2020.
Mr. Elmqvist completed his undergraduate degree at Imperial College London in 2018 and another undergraduate degree at Imperial College Business School in 2016.
Postes actifs de Karl Elmqvist
| Sociétés | Poste | Début |
|---|---|---|
AnaCardio AB
 AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Directeur/Membre du Conseil | 01/09/2022 |
Flerie Invest AB
 Flerie Invest AB Investment ManagersFinance Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden. | Private Equity Investor | 01/10/2022 |
Anciens postes connus de Karl Elmqvist
| Sociétés | Poste | Fin |
|---|---|---|
Guy's & St Thomas' Charity
 Guy's & St Thomas' Charity Services to the Health IndustryHealth Services Guy''s & St Thomas'' Charity operates as an independent, place-based foundation. It works with Guy’s and St Thomas’ NHS Foundation Trust and others to improve the health of people in the London boroughs of Lambeth and Southwark. The company is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 31/08/2021 |
Doctrin AB
 Doctrin AB Internet Software/ServicesTechnology Services Doctrin AB offers consultancy services within healthcare sector. It offers digital solutions that enable healthcare providers to prioritize, treat, and follow-up with their patients. The company was founded by Per Eriksson, Ashkan Labaf, Magnus Liungman, and Carslo Lorente in 2016 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | 31/05/2020 |
| Qvartz AB | Corporate Officer/Principal | 31/05/2018 |
| Imperial Consulting, Inc. | Corporate Officer/Principal | 31/03/2016 |
| Tetra Pak Holdings AB | Corporate Officer/Principal | 30/09/2015 |
Formation de Karl Elmqvist
| Imperial College London | Undergraduate Degree |
| Imperial College Business School | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
| Tetra Pak Holdings AB | |
| Imperial Consulting, Inc. | |
| Qvartz AB | |
Doctrin AB
Doctrin AB Internet Software/ServicesTechnology Services Doctrin AB offers consultancy services within healthcare sector. It offers digital solutions that enable healthcare providers to prioritize, treat, and follow-up with their patients. The company was founded by Per Eriksson, Ashkan Labaf, Magnus Liungman, and Carslo Lorente in 2016 and is headquartered in Stockholm, Sweden. | Technology Services |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Health Technology |
Guy's & St Thomas' Charity
Guy's & St Thomas' Charity Services to the Health IndustryHealth Services Guy''s & St Thomas'' Charity operates as an independent, place-based foundation. It works with Guy’s and St Thomas’ NHS Foundation Trust and others to improve the health of people in the London boroughs of Lambeth and Southwark. The company is headquartered in London, the United Kingdom. | Health Services |
Flerie Invest AB
Flerie Invest AB Investment ManagersFinance Flerie Invest AB (Flerie Invest) is a venture capital subsidiary of Flerie Creations Ltd. founded in 2011. The firm is headquartered in Stockholm, Sweden. | Finance |